Efficacy and safety of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials. J of Skin. 2022;6(6):s76. doi:10.25251/skin.6.supp.76